Aclaris Therapeutics, Inc. — Q1 2023 Form 10-Q Summary
Business context and reporting period
Aclaris Therapeutics is a clinical-stage biopharmaceutical company developing therapies for immuno-inflammatory diseases and pursuing licensing, partnering, and other strategic transactions. The filing covers the three months ended March 31, 2023, with comparative results for the three months ended March 31, 2022. The company also operates a contract research segment providing laboratory services.
Financial performance and position
| Metric | Q1 2023 | Q1 2022 | Change |
|---|---|---|---|
| Total revenue | $2.5 million | $1.5 million | +$1.1 million |
| Contract research revenue | $0.9 million | $1.2 million | -$0.3 million |
| Licensing revenue | $1.6 million | $0.2 million | +$1.4 million |
| Research and development expense | $22.6 million | $14.3 million | +$8.3 million |
| General and administrative expense | $8.8 million | $6.1 million | +$2.7 million |
| Loss from operations | $(29.9) million | $(18.9) million | Loss increased $11.0 million |
| Net loss | $(28.2) million | $(18.8) million | Loss increased $9.4 million |
| Net loss per share | $(0.42) | $(0.31) | |
| Net cash used in operating activities | $(26.4) million | $(21.0) million | Use increased $5.4 million |
Gross profit is not presented because management considers it an unmeaningful measure given the company’s revenue mix. Total costs and expenses were $32.4 million, compared with $20.4 million in the prior-year quarter. Stock-based compensation increased to $6.8 million from $2.3 million.
At March 31, 2023, cash and cash equivalents were $44.7 million and marketable securities were $159.7 million, for total cash, cash equivalents, and marketable securities of approximately $204.4 million. Total assets were $229.7 million and stockholders’ equity was $176.8 million. The company reported an accumulated deficit of $710.5 million.
The filing does not identify material outstanding debt or ongoing credit facilities. Liabilities included $32.3 million of contingent consideration, $2.6 million of operating lease liabilities, and $2.2 million related to discontinued operations. Remaining lease payment obligations were approximately $3.4 million as of March 31, 2023.
Material changes versus the prior comparable period
- Revenue increased primarily because licensing revenue included $1.4 million of royalty and milestone payments under the Eli Lilly agreement. Lilly-related licensing revenue was partly offset by $1.1 million payable to third parties.
- Contract research revenue declined because of lower hours billed, partially offset by higher average billing rates.
- Research and development spending increased 58%, reflecting higher costs for zunsemetinib, ATI-1777, ATI-2138, personnel, manufacturing, and clinical development activities.
- General and administrative expense increased 44%, primarily from higher personnel costs, stock-based compensation, professional fees, and patent expenses.
- Operating cash use increased as the company incurred higher losses. Investing activities provided $25.8 million, largely because proceeds from marketable securities exceeded purchases.
- The fair value of contingent consideration decreased by $0.8 million, primarily following removal of estimated sales for zunsemetinib in hidradenitis suppurativa after the company discontinued that indication.
- Shares outstanding increased to 67.2 million at March 31, 2023 from 66.7 million at December 31, 2022, principally from restricted stock unit vesting.
Guidance, outlook, risks, and unusual items
- Management expects continued net losses and significant research and development spending as it advances zunsemetinib, ATI-1777, ATI-2138, preclinical programs, and discovery activities.
- Expected development milestones include zunsemetinib rheumatoid arthritis topline data in the fourth quarter of 2023, ATI-1777 topline data in the second half of 2023, ATI-2138 topline data in the second half of 2023, and zunsemetinib psoriatic arthritis topline data in the first half of 2024.
- The company announced in March 2023 that the zunsemetinib hidradenitis suppurativa trial failed to meet its primary and secondary efficacy endpoints and that it would not pursue the indication further.
- ATI-2231 clinical development activities were expected to begin in 2023, potentially through an academic collaboration.
- Management believes existing cash, cash equivalents, and marketable securities are sufficient to fund operating and capital requirements for more than 12 months from the financial statement issuance date. However, additional capital will be required to complete clinical development and support preclinical and discovery programs.
- In March 2023, the company issued a notice to sell 3.4 million shares under an at-the-market facility for gross proceeds of $27.5 million. The sale closed in April 2023, with $0.8 million of selling commissions.
- Key risks include clinical trial failure or delay, regulatory nonapproval, inability to secure partnerships or financing, dilution from future equity offerings, dependence on third-party manufacturers, market and interest-rate volatility, and macroeconomic conditions including banking disruptions and inflation.
- The company had no material legal proceedings pending as of the filing date, and management reported no material changes to previously disclosed risk factors or internal control effectiveness.
Most important facts for investors to verify
- Whether the approximately $204.4 million liquidity balance and April 2023 ATM proceeds adequately fund the current development plan and expected cash burn.
- The timing and results of the 2023 clinical readouts for zunsemetinib, ATI-1777, and ATI-2138.
- The implications of the failed hidradenitis suppurativa study for zunsemetinib’s broader development strategy and contingent consideration liability.
- The sustainability and economic value of licensing and royalty revenue, particularly after payments owed to third parties.
- The potential dilution from outstanding options and restricted stock units, totaling approximately 8.6 million potential shares at March 31, 2023.
- The amount and timing of possible future contingent consideration payments of up to $75.0 million under the Confluence acquisition agreement, plus potential royalties and transaction-related payments.